Cargando…

A feasibility study of objective outcome measures used in clinical trials of freezing of gait

BACKGROUND: Freezing of gait (FOG) is notoriously difficult to quantify, which has led to the use of multiple markers as outcomes for clinical trials. The instrumented timed up and go (TUG) and the many parameters that can be derived from it are commonly used as objective markers of FOG severity in...

Descripción completa

Detalles Bibliográficos
Autores principales: Revuelta, Gonzalo J., Embry, Aaron, Elm, Jordan J., Jenkins, Shonna, Lee, Philip, Kautz, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252072/
https://www.ncbi.nlm.nih.gov/pubmed/35787816
http://dx.doi.org/10.1186/s40814-022-01092-2
_version_ 1784740181328265216
author Revuelta, Gonzalo J.
Embry, Aaron
Elm, Jordan J.
Jenkins, Shonna
Lee, Philip
Kautz, Steve
author_facet Revuelta, Gonzalo J.
Embry, Aaron
Elm, Jordan J.
Jenkins, Shonna
Lee, Philip
Kautz, Steve
author_sort Revuelta, Gonzalo J.
collection PubMed
description BACKGROUND: Freezing of gait (FOG) is notoriously difficult to quantify, which has led to the use of multiple markers as outcomes for clinical trials. The instrumented timed up and go (TUG) and the many parameters that can be derived from it are commonly used as objective markers of FOG severity in clinical trials; however, it is unknown if they represent actual FOG severity. OBJECTIVE: To determine the specificity and responsiveness of objective surrogate markers of FOG severity commonly utilized in FOG studies. METHODS: Study design: We compared the specificity and responsiveness of commonly used markers in FOG clinical trials. Markers compared included velocity, step/stride length, step/stride length variability, TUG, and turn duration. Data was collected in four conditions (ON and OFF dopaminergic drugs, with and without a dual task). Unified Parkinson’s Disease Rating Scale (UPDRS) was administered in the ON and OFF states. RESULTS: Thirty-three subjects were recruited (17 PD subjects without FOG (PD-control) and 16 subjects with PD and dopa-responsive FOG PD-FOG). The UPDRS motor scores were 24.9 for the PD-control group in the ON state, 24.8 for the FOG group in the ON state, and 42.4 for the FOG group in the OFF state. Significant mean differences between the ON and OFF conditions were observed with all surrogate markers (p < 0.01). However, only dual task turn duration and step variability showed trends toward significance when comparing PD-control and ON-FOG (p = 0.08). Test–retest reliability was high (ICC > 0.90) for all markers except standard deviations. Step length variability was the only marker to show an area under the ROC curve analysis > 0.70 comparing ON-FOG vs. PD-control. CONCLUSIONS: Multiple candidate surrogate markers for FOG severity showed responsiveness to levodopa challenge; however, most were not specific for FOG severity.
format Online
Article
Text
id pubmed-9252072
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92520722022-07-05 A feasibility study of objective outcome measures used in clinical trials of freezing of gait Revuelta, Gonzalo J. Embry, Aaron Elm, Jordan J. Jenkins, Shonna Lee, Philip Kautz, Steve Pilot Feasibility Stud Research BACKGROUND: Freezing of gait (FOG) is notoriously difficult to quantify, which has led to the use of multiple markers as outcomes for clinical trials. The instrumented timed up and go (TUG) and the many parameters that can be derived from it are commonly used as objective markers of FOG severity in clinical trials; however, it is unknown if they represent actual FOG severity. OBJECTIVE: To determine the specificity and responsiveness of objective surrogate markers of FOG severity commonly utilized in FOG studies. METHODS: Study design: We compared the specificity and responsiveness of commonly used markers in FOG clinical trials. Markers compared included velocity, step/stride length, step/stride length variability, TUG, and turn duration. Data was collected in four conditions (ON and OFF dopaminergic drugs, with and without a dual task). Unified Parkinson’s Disease Rating Scale (UPDRS) was administered in the ON and OFF states. RESULTS: Thirty-three subjects were recruited (17 PD subjects without FOG (PD-control) and 16 subjects with PD and dopa-responsive FOG PD-FOG). The UPDRS motor scores were 24.9 for the PD-control group in the ON state, 24.8 for the FOG group in the ON state, and 42.4 for the FOG group in the OFF state. Significant mean differences between the ON and OFF conditions were observed with all surrogate markers (p < 0.01). However, only dual task turn duration and step variability showed trends toward significance when comparing PD-control and ON-FOG (p = 0.08). Test–retest reliability was high (ICC > 0.90) for all markers except standard deviations. Step length variability was the only marker to show an area under the ROC curve analysis > 0.70 comparing ON-FOG vs. PD-control. CONCLUSIONS: Multiple candidate surrogate markers for FOG severity showed responsiveness to levodopa challenge; however, most were not specific for FOG severity. BioMed Central 2022-07-04 /pmc/articles/PMC9252072/ /pubmed/35787816 http://dx.doi.org/10.1186/s40814-022-01092-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Revuelta, Gonzalo J.
Embry, Aaron
Elm, Jordan J.
Jenkins, Shonna
Lee, Philip
Kautz, Steve
A feasibility study of objective outcome measures used in clinical trials of freezing of gait
title A feasibility study of objective outcome measures used in clinical trials of freezing of gait
title_full A feasibility study of objective outcome measures used in clinical trials of freezing of gait
title_fullStr A feasibility study of objective outcome measures used in clinical trials of freezing of gait
title_full_unstemmed A feasibility study of objective outcome measures used in clinical trials of freezing of gait
title_short A feasibility study of objective outcome measures used in clinical trials of freezing of gait
title_sort feasibility study of objective outcome measures used in clinical trials of freezing of gait
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252072/
https://www.ncbi.nlm.nih.gov/pubmed/35787816
http://dx.doi.org/10.1186/s40814-022-01092-2
work_keys_str_mv AT revueltagonzaloj afeasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait
AT embryaaron afeasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait
AT elmjordanj afeasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait
AT jenkinsshonna afeasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait
AT leephilip afeasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait
AT kautzsteve afeasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait
AT revueltagonzaloj feasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait
AT embryaaron feasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait
AT elmjordanj feasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait
AT jenkinsshonna feasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait
AT leephilip feasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait
AT kautzsteve feasibilitystudyofobjectiveoutcomemeasuresusedinclinicaltrialsoffreezingofgait